2023-12-27
日前，海問香港辦公室助力中國寶原投資有限公司（“中國寶原”）就中國核工業集團有限公司（“中核集團”）將其直接持有的全部106,676,903股中國同輻股份有限公司（“中國同輻”，1763.HK）的內資股（約占中國同輻全部已發行股本總額的33.35%）無償劃轉（“無償劃轉”）至中國寶原順利完成。本次無償劃轉完成后，中國寶原成為中國同輻的直接控股股東，而中核集團仍為中國同輻的最終控制股東。
中核集團于1999年6月29日成立，是經國務院批準組建、中央直接管理的國有重要骨干企業，是國家核科技工業的主體、核能發展與核電建設的中堅、核技術應用的骨干，擁有完整的核科技工業體系。中國寶原為中核集團全資子公司，致力于落實中核集團核技術應用產業發展中長期戰略，業務覆蓋核技術應用絕大部分領域，形成了從技術、產品到服務應用的產業鏈。通過整合研發、生產、銷售和服務，中國寶原鞏固了其在核技術行業與醫學應用領域的領先地位。中國同輻為香港聯交所主板上市公司，自1983年成立以來，在核技術應用領域已深耕40年，聚焦藥品的研發、生產、銷售，同時兼營放射源、輻照、核醫療裝備和獨立醫學檢驗實驗室服務，是國內核技術應用領域的領軍企業。
海問香港辦公室作為中國寶原的香港法律顧問，全面配合客戶需要，就本次無償劃轉所涉法律法規及其他重大問題適時與各方進行溝通和交流。海問香港辦公室憑借其對香港法律法規以及各監管機構的規則與指引等的扎實理解和豐富的交易類法律服務經驗，就項目方案整體規劃、審閱交易文件、遵守信息披露義務、相關豁免申請、與監管部門溝通等方面，為客戶提供了專業的法律建議和及時且適切的全流程解決方案，助力本次無償劃轉順利完成。海問香港辦公室在本項目中提供的高質及高效的法律服務獲得了客戶的高度評價。
Recently, Haiwen Hong Kong assisted China Baoyuan Investment Co., Ltd. (“China Baoyuan”) in successful completion of the gratuitous transfer by China National Nuclear Corporation (“CNNC”) of all 106,676,903 domestic shares in China Isotope & Radiation Corporation (“CIRC”, 1763.HK) directly held by it (the “Gratuitous Transfer”), representing approximately 33.35% of CIRC’s total issued share capital, to China Baoyuan. Upon completion of the Gratuitous Transfer, China Baoyuan has become a direct controlling shareholder of CIRC, while CNNC remains the ultimate controlling shareholder of CIRC.
CNNC was established on 29 June 1999 as approved by the State Council and is a state-owned backbone enterprise directly administered by the central government. Equipping with a complete nuclear science and technology industry system, CNNC plays a key role in the fields of national nuclear science and technology industry, nuclear energy development and nuclear power construction, and nuclear technology application. China Baoyuan is a wholly-owned subsidiary of CNNC and specialises in implementing CNNC’s medium and long-term development strategy for its nuclear technology application business, forging an industry chain that covers most aspects of nuclear technology application, from technology, products to service applications. China Baoyuan cemented its lead in the nuclear technology industry and in medical applications through its integration of research and development, production, sales, and services. CIRC, a company listed on the main board of The Stock Exchange of Hong Kong, has been exploring the field of nuclear technology application for 40 years since its establishment in 1983. As a leading enterprise in the nuclear technology application industry in China, CIRC focuses on research and development, manufacturing, sales of pharmaceuticals and is also engaged in radioactive sources, irradiation, nuclear medical equipment and independent clinical laboratory services.
As the Hong Kong legal adviser to China Baoyuan, Haiwen Hong Kong has fully accommodated the needs of its client, as well as timely communicated and exchanged views with various professional parties on the relevant laws and regulations and other material issues involved in the Gratuitous Transfer. With its solid understanding of Hong Kong laws and regulations and the rules and guidelines of various regulatory bodies, as well as extensive experience in transactional legal services, Haiwen Hong Kong provided professional legal advice and timely and appropriate solutions to its client at all stages of the project on overall transactional structure design, reviewing of transaction documents, fulfilling public information disclosure obligations, waiver applications, and communication with regulatory authorities, etc. which are instrumental to the successful completion of the Gratuitous Transfer. Haiwen Hong Kong has received high acclaim from its client for the high-quality and efficient legal services provided in this project.
The team from Haiwen advising on this project was led by international partner Isaac Chen, and assisted by associates Henry Ho, Anna Mak, Yuda Chen and Aiye Jia, and paralegal Xuanchi Jing.
日前，海問香港辦公室助力中國寶原投資有限公司（“中國寶原”）就中國核工業集團有限公司（“中核集團”）將其直接持有的全部106,676,903股中國同輻股份有限公司（“中國同輻”，1763.HK）的內資股（約占中國同輻全部已發行股本總額的33.35%）無償劃轉（“無償劃轉”）至中國寶原順利完成。本次無償劃轉完成后，中國寶原成為中國同輻的直接控股股東，而中核集團仍為中國同輻的最終控制股東。
中核集團于1999年6月29日成立，是經國務院批準組建、中央直接管理的國有重要骨干企業，是國家核科技工業的主體、核能發展與核電建設的中堅、核技術應用的骨干，擁有完整的核科技工業體系。中國寶原為中核集團全資子公司，致力于落實中核集團核技術應用產業發展中長期戰略，業務覆蓋核技術應用絕大部分領域，形成了從技術、產品到服務應用的產業鏈。通過整合研發、生產、銷售和服務，中國寶原鞏固了其在核技術行業與醫學應用領域的領先地位。中國同輻為香港聯交所主板上市公司，自1983年成立以來，在核技術應用領域已深耕40年，聚焦藥品的研發、生產、銷售，同時兼營放射源、輻照、核醫療裝備和獨立醫學檢驗實驗室服務，是國內核技術應用領域的領軍企業。
海問香港辦公室作為中國寶原的香港法律顧問，全面配合客戶需要，就本次無償劃轉所涉法律法規及其他重大問題適時與各方進行溝通和交流。海問香港辦公室憑借其對香港法律法規以及各監管機構的規則與指引等的扎實理解和豐富的交易類法律服務經驗，就項目方案整體規劃、審閱交易文件、遵守信息披露義務、相關豁免申請、與監管部門溝通等方面，為客戶提供了專業的法律建議和及時且適切的全流程解決方案，助力本次無償劃轉順利完成。海問香港辦公室在本項目中提供的高質及高效的法律服務獲得了客戶的高度評價。
Recently, Haiwen Hong Kong assisted China Baoyuan Investment Co., Ltd. (“China Baoyuan”) in successful completion of the gratuitous transfer by China National Nuclear Corporation (“CNNC”) of all 106,676,903 domestic shares in China Isotope & Radiation Corporation (“CIRC”, 1763.HK) directly held by it (the “Gratuitous Transfer”), representing approximately 33.35% of CIRC’s total issued share capital, to China Baoyuan. Upon completion of the Gratuitous Transfer, China Baoyuan has become a direct controlling shareholder of CIRC, while CNNC remains the ultimate controlling shareholder of CIRC.
CNNC was established on 29 June 1999 as approved by the State Council and is a state-owned backbone enterprise directly administered by the central government. Equipping with a complete nuclear science and technology industry system, CNNC plays a key role in the fields of national nuclear science and technology industry, nuclear energy development and nuclear power construction, and nuclear technology application. China Baoyuan is a wholly-owned subsidiary of CNNC and specialises in implementing CNNC’s medium and long-term development strategy for its nuclear technology application business, forging an industry chain that covers most aspects of nuclear technology application, from technology, products to service applications. China Baoyuan cemented its lead in the nuclear technology industry and in medical applications through its integration of research and development, production, sales, and services. CIRC, a company listed on the main board of The Stock Exchange of Hong Kong, has been exploring the field of nuclear technology application for 40 years since its establishment in 1983. As a leading enterprise in the nuclear technology application industry in China, CIRC focuses on research and development, manufacturing, sales of pharmaceuticals and is also engaged in radioactive sources, irradiation, nuclear medical equipment and independent clinical laboratory services.
As the Hong Kong legal adviser to China Baoyuan, Haiwen Hong Kong has fully accommodated the needs of its client, as well as timely communicated and exchanged views with various professional parties on the relevant laws and regulations and other material issues involved in the Gratuitous Transfer. With its solid understanding of Hong Kong laws and regulations and the rules and guidelines of various regulatory bodies, as well as extensive experience in transactional legal services, Haiwen Hong Kong provided professional legal advice and timely and appropriate solutions to its client at all stages of the project on overall transactional structure design, reviewing of transaction documents, fulfilling public information disclosure obligations, waiver applications, and communication with regulatory authorities, etc. which are instrumental to the successful completion of the Gratuitous Transfer. Haiwen Hong Kong has received high acclaim from its client for the high-quality and efficient legal services provided in this project.
The team from Haiwen advising on this project was led by international partner Isaac Chen, and assisted by associates Henry Ho, Anna Mak, Yuda Chen and Aiye Jia, and paralegal Xuanchi Jing.
京ICP備05019364號-1 
京公網安備110105011258